Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of scabies, a skin condition caused by tiny mites that burrow into the skin, leading to intense itching and a rash. The study will use two main treatments: InfectoScab® 5% cream, which contains the active ingredient permethrin, and a higher concentration permethrin 10% cream. Additionally, DRIPONIN 3 mg tablets, containing ivermectin, may be used if needed. The purpose of the study is to evaluate the effectiveness and safety of these treatments in managing scabies.

The study will be conducted in two stages. In the first stage, participants will receive the standard treatment with InfectoScab® 5% cream, applied once or twice as needed. The success of this treatment will be assessed after 14 or 28 days, depending on the number of applications. If the initial treatment is not successful, the second stage will involve using the higher concentration permethrin 10% cream. Participants in this stage will be divided into different groups to test the effectiveness of one or two applications of the cream, with results evaluated after 14, 21, or 28 days.

Throughout the study, the effectiveness of the treatments will be monitored by checking for the presence of mites and any new skin symptoms. Participants will also be asked about changes in itching levels. The study aims to find the most effective treatment regimen for scabies, ensuring that patients receive the best possible care. The trial will continue until the end of 2026, with the goal of providing valuable insights into the treatment of this common skin condition.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    Upon joining the study, you will begin the initial treatment phase for scabies. This involves using a cream called InfectoScab 5%, which contains the active ingredient permethrin. The cream is applied to the skin.

    You will apply the cream once, covering your entire body. If necessary, a second application may be required. The treatment success will be evaluated on day 14 if only one application is needed, or on day 28 if a second application is required.

  2. Step 2

    Evaluation of initial treatment

    After completing the initial treatment phase, the effectiveness of the treatment will be assessed. This involves checking for the presence of scabies mites or symptoms.

    If the initial treatment is successful, no further action is needed. If the treatment is not successful, you will proceed to the next phase of the study.

  3. Step 3

    Escalated treatment phase

    If the initial treatment does not succeed, you will enter the escalated treatment phase. This phase involves using a higher concentration of permethrin cream, specifically a 10% formulation.

    In this phase, you may be placed in one of two study arms. In study arm A, you will apply the 10% permethrin cream once, with a possible second application if needed. In study arm B, you will apply the cream twice. The treatment success will be evaluated 14 days after the last application for arm A, and on day 21 for arm B.

  4. Step 4

    Final evaluation

    The final evaluation will determine the overall success of the treatment. This involves checking for any remaining signs of scabies and assessing any side effects or reactions to the treatment.

    The study will conclude with this evaluation, and you will be informed of the results and any further recommendations.

Who can join the trial?

4 criteria

  • Must have a confirmed case of scabies. This means that mites, mite nymphs, or mite larvae have been found on the skin using a special type of microscope.
  • Must be between 6 and 85 years old for the first part of the study, or between 2 and 85 years old for the second part of the study.
  • Must provide a written consent to participate. If you are an adult, you can give this consent yourself. If you are under 12 years old, your legal guardians must give consent. If you are 12 years or older but not yet an adult, both you and your legal guardians must give consent.
  • The study medication must be applied by trained specialist staff at the trial site. If this is not possible, there must be a third person, like a close contact, who can help apply the medication to areas you cannot reach.

Who cannot join the trial?

5 criteria

  • Patients who are not diagnosed with scabies cannot participate. Scabies is a skin condition caused by tiny mites.
  • Patients who are not within the specified age range cannot participate. The age range includes children and adults.
  • Patients who are not part of the specified clinical trial groups cannot participate.
  • Patients who are not male or female cannot participate.
  • Patients who are not considered part of a vulnerable population cannot participate. A vulnerable population includes groups who may need special protection.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • InfectoScab

    is a cream used to treat scabies, a skin condition caused by tiny mites that burrow into the skin. This cream contains permethrin, which is a medication that kills the mites and their eggs. In the clinical trial, patients apply the cream to their entire body to see if it effectively clears the scabies infection. The treatment may involve one or two applications, depending on the patient's response.

  • Permethrin Cream

    is another form of treatment for scabies being tested in the trial. Like InfectoScab, it is applied to the skin to eliminate the mites causing the infection. The trial is investigating the effectiveness of a higher concentration of permethrin cream. Patients may need to apply the cream once or twice, and the trial aims to determine how well this treatment works in clearing the infection.

What is already known about the treatment

InfectoScab 5% Cream – This medication is applied topically as a cream to treat scabies, a skin condition caused by tiny mites. It is currently used in medical practice and is well-documented in medical literature for its effectiveness. The main therapeutic indication is the treatment of scabies, and it works by disrupting the nervous system of the mites, leading to their death. InfectoScab 5% Cream is classified as an antiparasitic medication.

Investigated diseases

Scabies – Scabies is a skin condition caused by an infestation of the human itch mite, Sarcoptes scabiei. The mites burrow into the upper layer of the skin, where they live and lay eggs. This causes intense itching and a pimple-like skin rash. The condition spreads through direct, prolonged skin-to-skin contact with an infested person. The itching is often more severe at night and can lead to scratching, which may cause skin sores. These sores can sometimes become infected with bacteria, leading to further complications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-513288-14-00Protocol codeETSKABIEstimated enrolment263 patientsSponsorINFECTOPHARM Arzneimittel und Consilium GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).